CN1528150A - Biological agent for foot disinfection - Google Patents

Biological agent for foot disinfection Download PDF

Info

Publication number
CN1528150A
CN1528150A CNA2003101079830A CN200310107983A CN1528150A CN 1528150 A CN1528150 A CN 1528150A CN A2003101079830 A CNA2003101079830 A CN A2003101079830A CN 200310107983 A CN200310107983 A CN 200310107983A CN 1528150 A CN1528150 A CN 1528150A
Authority
CN
China
Prior art keywords
biologic product
preparation
foot
cream
foot sterilization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2003101079830A
Other languages
Chinese (zh)
Other versions
CN100431419C (en
Inventor
陆婉英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANGHAI GAOKE BIO-ENGINEERING Co Ltd
Original Assignee
SHANGHAI GAOKE BIO-ENGINEERING Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI GAOKE BIO-ENGINEERING Co Ltd filed Critical SHANGHAI GAOKE BIO-ENGINEERING Co Ltd
Priority to CNB2003101079830A priority Critical patent/CN100431419C/en
Publication of CN1528150A publication Critical patent/CN1528150A/en
Application granted granted Critical
Publication of CN100431419C publication Critical patent/CN100431419C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to a biological preparation for pedal disinfection. Said biological preparation comprises 0.0001-0.0 wt% of lysostaphin and pharmaceutically-aceptable carrier, the described carrier includes water, gel matrix and emulsion matrix. Said preparation also contains 0.001-5% of lysozyme, 0.5-50% of protein stabilizing agnet, skin-moistening agent and proper quantity of emulsifying agent. Said preparation has strong germicidal effect, broad bactericidal spectrum, strong stability, has no drug-resistance and is non-toxic and is non-irritant.

Description

A kind of biologic product that is used for the foot sterilization
Technical field
The present invention relates to a kind of biotype biocide preparation, specifically, relate to a kind of biologic product that is used for the foot sterilization.
Background technology
The foot bacterial infection is a common phenomenon in the daily life.Pedal skin is the same with the skin at other positions of health, and all in ceaselessly metabolism, all have scurf to come off at any time every day.Scurf will mix savings in toe seam and skin fold with sweat and dust etc., easy parasitic mould, red hair moss bacterium, staphylococcus aureus, Candida albicans and proteus etc.
On daytime, the foot temperature and humidity that is wrapped in the footgear increases, and growth of bacterium and breeding are quickened; This outer contacting is caused infection easily by the slippers of germ contamination, towel, bathtub etc.; The specific crowd of some hypoimmunity, as chronic bed patient, diabetes patient and other immunodeficiencies patient etc. are more than the foot bacterial infection height to 90%; In a word, foot is one of position of the easiest generation infection of human body.
The cardinal symptom of foot bacterial infection comprises that phenomenons such as blister type and rotten to the corn moist type take place the papule scales of skin that peel off or angling to occur.Tinea pedis or secondary infection also can cause lymphedema, and serious infectious lymphedema need be passed through operative treatment.Therefore, control fungal infection is one of effective and the easiest measure of prevention lymphedema.
The product for the treatment of the foot infection in the market mainly contains two classes: a class is an antifungal drug, as salicylate compound tincture, miconazole nitrate, compound resorcinol liniment, 1% clotrimazole cream, rotten alumen powder and berberi powder; Another kind of is chloride sterile products.The latter wherein, to mucocutaneous, particularly the excitant of damaged skin is very strong.And the former is easy to generate drug resistance, often when using the first time, take effect fast, but recurrence easily, and recurrence in a single day, then effect obviously weakens.Secondly, this two series products has certain chemistry injury to skin, causes the local skin drying easily, and peculiar smell is also often arranged.Combine and more to lack the specific crowd that is fit to hypoimmunity in the market, can use for a long time, have no drug resistance and the product of toxic and side effect.
Summary of the invention
The technical issues that need to address of the present invention are to provide a kind of biologic product that is used for the foot sterilization, and are big to overcome the toxic and side effect that prior art exists, strong to skin and mucous membrane irritation, and easily produce drug resistance, the easy defective of recurrence.
The invention provides a kind of biologic product that is used for foot sterilization, skin care, said preparation comprises that weight percent content is the staphylococcus lysozyme of 0.0001-0.1% and pharmaceutically acceptable carrier.
Staphylococcus lysozyme wherein is one or more in agriotype, reorganization generation, mutant or any reorganization that contains the glycine cross-bond that keeps the antistaphylohemolysin whole cell peptidoglycan or the relevant enzyme; Staphylococcus lysozyme derives from Staphylococus Simulans and secretes protein product outside born of the same parents, and the nucleic acid of its gene is formed 1486 nucleotide; Molecular weight of albumen 6803Da, form by 244 amino acid, WO0129201 (Expression of recombinant muture lysostaphin) and DE4425645 (New lysostaphin gene with deletion in pro-segment repeatregion) have reported the staphylococcus lysozyme of reorganization and the staphylococcus lysozyme of sudden change respectively, but its bactericidal activity remains unchanged.The sterilization mechanism of staphylococcus lysozyme is by the glycine key in the narrow spectrum cut-out muramyl peptide glycan, reaches the effect of quick kill pathogenic organisms.Used staphylococcus lysozyme is that Gaoke Bio-Engineering Co Ltd, Shanghai produces by gene recombination technology, by hay bacillus amplification secretion, the specific activity scope of its enzyme is 300-1200 unit/milligram;
Said carrier comprises that water, gel are with matrix or cream matrix.
Gel comprises in glycerin gelatine, starch, cellulose derivatives, the polyethylene glycol one or more with matrix;
Cream comprises one or more and emulsifier in hydroxyl class, grease class or the lipoid with matrix;
Wherein:
The hydroxyl class comprises a kind of in vaseline, solid paraffin, atoleine or the silicone etc.;
The grease class comprises a kind of in peanut oil, cotton seed oil or the hydrogenated vegetable wet goods;
Lipoid comprises a kind of in lanolin, beeswax or the cholesterol etc.
Cream comprises one or more in naturally occurring emulsifying agent or the synthetic emulsifier, naturally occurring emulsifying agent wherein such as gum Arabic, animal glue, alginate, lecithin etc.; Synthetic emulsifier such as cellulose derivatives, tristerin, sucrose fatty ester class, tween (Tween) etc., its addition are 2～15% of cream usefulness matrix weight.
Also contain the lysozyme that weight percent content is 0.001-5% in the said preparation, lysozyme is one or more in bacterial cell wall lyase, saccharomycete cell wall lyase, the mould cell wall lyase; Used lysozyme is the active component that extracts from egg white, is the bulk drug that meets the Chinese Pharmacopoeia standard, and lysozyme is by acting on β-1,4 glycosidic bond in the cell wall or β-1,3 glucan and killing bacteria.Not only can work in coordination with staphylococcus lysozyme and strengthen sterilizing function, can strengthen the biological stability of staphylococcus lysozyme simultaneously.
In order to strengthen the shelf stability of staphylococcus lysozyme, needing to add weight percent content is the protein stabilizing agent of 0.5-50%, employed protein stabilizing agent is medicinal macromolecular compounds such as polyethylene glycol substances or shitosan, chitin, N-acetyl-D-amino among the present invention, can wrap up protein or polypeptide, the destruction of avoiding other materials, thereby the stability of enhancing protein or polypeptide.
Simultaneously in order to make said preparation certain nursing role be arranged to skin, add the emollient of preparation total amount 0.5～20% and an amount of emulsifier, preferred emollient comprises one or more in water-soluble modified silicone oil, cation-modified silicone oil, amino-modified silicone oil and the amino composite modified silicone oil, emulsifier is one or more in naturally occurring emulsifying agent or the synthetic emulsifier, naturally occurring emulsifying agent wherein such as gum Arabic, animal glue, alginate, lecithin etc.; Synthetic emulsifier such as cellulose derivatives, tristerin, sucrose fatty ester class, tween (Tween) etc., addition is 2～10% of a weight of formulation.
When carrier is water, be aqua; When carrier is a gel when using matrix, be gel; When carrier is a cream when using matrix, be cream.
Said preparation has following characteristics:
1. bactericidal effect is strong, and fungicidal spectrum is wide;
Said preparation is to gram-positive bacteria and Gram-negative bacteria and part is viral and fungi is all effective, especially staphylococcus aureus, red hair moss bacterium, Pseudomonas aeruginosa, Candida albicans etc., the experiment in vitro effect can reach 99.9% sterilizing rate in 5 minutes, if act on 10 minutes even 20 minutes, can make sterilizing rate reach 100%.(as table 1-4).
2. two kinds of biology enzymes are composite, and stability is strong, and 54 ℃ to deposit 2 all bactericidal activities constant;
The present invention carries out staphylococcus lysozyme and lysozyme composite, not only kept bactericidal activity separately, and because can interact between the various compositions, experimental results show that, after composite not only bactericidal activity strengthen (10-40 doubly to the simple superposition of three's bactericidal effect) greatly than three's bactericidal activity separately, and the stability of biology enzyme is strengthened, add other protein stabilizing agent, deposit 2 week backs (being equivalent to normal temperature preserved 2 years) for 54 ℃, said preparation remains unchanged to the bactericidal activity of red hair moss bacterium, still, act on 20 minutes and can reach 100% more than 99.9%.(as table 5).
3. be pure biologic product and medically acceptable carrier, overcome traditional chemical class preparation the foot fungus infection obstinate, easily recurrence, bacterium is easy to generate chemical sproof shortcoming.
4. this preparation is pure biologic product, pedal skin, and without any toxic and side effect.The acute and chronic toxicological test result who carries out through sterilization section of Shanghai Disease Prevention and Control Centre shows that said preparation is nontoxic non-stimulated product.
The present invention also provides the preparation method of this biologic product, in desinfection chamber, with the abundant mixing of various components, gets final product.Said preparation can be used for preventing and treats the beriberi that caused by fungi or bacterial infection, pin moss, onychomycosis, skin moss etc.
Its basic characteristics are:
One. sterilizing power is strong, and fungicidal spectrum is wide
1. to the killing effect of staphylococcus aureus
Foot disinfectant stock solution, 50%, 25% dilution act on 5min, 10min, 20min respectively, and the killing effect of staphylococcus aureus is respectively 99.99%, 99.92%, 99.96%.
The killing effect of table 1 pair staphylococcus aureus
The average kill ratio and the scope of diluted concentration effect different time (min)
(％) 2 5 10 20
Stoste 99.86 99.99 100 100
(99.85-99.87) (99.98-100)
50 99.28 99.85 99.92 99.99
(99.22-99.34) (99.84-99.86) (99.90-99.94) (99.99-100)
25 98.09 99.38 99.70 99.96
(97.86-98.34) (99.35-99.42) (99.68-99.71) (99.95-99.98)
Annotate: average bacterium number of positive controls and scope are 7.25 * 10 5Cfu/ sheet (7.15-7.35 * 10 5The cfu/ sheet) negative control group: neutralizer, PBS, medium do not have bacterial growth.
2. to the oidiomycetic killing effect of white
Foot disinfectant stock solution, 50% dilution act on 5min, 20min respectively, and the oidiomycetic average kill ratio of white is respectively 99.97%, 99.94%.
The oidiomycetic killing effect of table 2 pair white
The average kill ratio and the scope of diluted concentration effect different time (min)
(％) 2 5 10 20
Stoste 99.74 99.97 99.99 100
(99.71-99.78) (99.97-99.98) (99.99-100)
50 99.31 99.73 99.89 99.94
(99.26-99.35) (99.70-99.76) (99.88-99.90) (99.94-99.95)
25 97.19 99.01 99.41 99.83
(97.00-97.50) (98.90-99.11) (99.36-99.48) (99.82-99.84)
Annotate: average bacterium number of positive controls and scope are 6.00 * 10 5Cfu/ sheet (5.80-6.20 * 10 5The cfu/ sheet) negative control group: neutralizer, PBS, medium do not have bacterial growth.
3. to colibacillary killing effect
Foot disinfectant stock solution, 50%, 25% dilution act on 2min, 10min, 20min respectively, and colibacillary average kill ratio is respectively 99.93%, 99.99%, 99.98%.
Table 3 pair colibacillary killing effect
The average kill ratio and the scope of diluted concentration effect different time (min)
(％) 2 5 10 20
Stoste 99.93 99.99 100 100
(99.92-99.94) (99.99-99.99)
50 99.57 99.89 99.99 100
(99.51-99.62) (99.88-99.90) (99.99-99.99)
25 98.96 99.63 99.79 99.98
(98.88-99.05) (99.60-99.67) (99.75-99.81) (99.98-99.98)
Annotate: average bacterium number of positive controls and scope are 7.00 * 10 5Cfu/ sheet (6.80-7.20 * 10 5The cfu/ sheet) negative control group: neutralizer, PBS, medium do not have bacterial growth.
4. to the killing effect of Trichophyton rubrum
Foot disinfectant stock solution, 75%, 50% dilution act on 5min, 10min, 20min respectively, and the average kill ratio of Trichophyton rubrum is respectively 99.90%, 99.97%, 99.99%.
The killing effect of table 4 pair red hair moss bacterium
The average kill ratio and the scope of diluted concentration effect different time (min)
(％) 2 5 10 20
Stoste 99.91 99.97 99.99 100
(99.90-99.92) (99.96-99.99) (99.99-100)
75 97.99 99.90 99.97 99.99
(97.89-98.12) (99.88-99.97) (99.96-99.99) (99.99-100)
50 92.10 99.04 99.89 99.99
(91.99-92.89) (99.00-99.10) (99.86-99.93) (99.99-99.99)
Annotate: average bacterium number of positive controls and scope are 1.86 * 10 6Cfu/ sheet (1.82-1.89 * 10 6The cfu/ sheet) negative control group: neutralizer, PBS, medium do not have bacterial growth.
Two. good stability
Table 5 is deposited after 14 days the killing effect to red hair moss bacterium
The average clump count of storage temperature control group and effect different time (min) average kill ratio and scope (%)
And time scope 25 10 20
(℃, d) (cfu/ sheet)
54?14 5.80×10 5 99.69 99.93 99.98 100
(99.69-
(5.70-5.90×10 5) (99.93-99.94) (99.97-99.99)
99.70)
Annotate: negative control group does not have bacterial growth.
Three. have no side effect
Acute oral toxicity test: mouse LD 50＞5000mg/kg, the nontoxic level in true border;
Skin irritatin test: belong to nonirritant;
Cumulative toxicity test: cumulative coefficient K＞5, the property accumulated a little less than the genus;
Micronucleus test: do not have the micronucleus effect that causes.
Embodiment
Embodiment 1
Staphylococcus lysozyme 0.0001 gram, lysozyme 5 grams, cetomacrogol 1000 20 grams, shitosan 1 gram, water is supplied 100 grams.
Add an amount of distilled water in the aseptic agitator, add other components of aforementioned proportion then respectively, abundant stirring and evenly mixing, adding distil water to 100 restrains again, mixing, can gets final product.
Embodiment 2
Staphylococcus lysozyme 0.1 gram, lysozyme 0.001 gram, cetomacrogol 1000 20 grams, shitosan 5 grams, vaseline 3 grams, tween 2 grams, Myrj 45 30 grams.
Said components is proportionally added respectively in the sterile chamber, stir, make the emulsifiable paste shape, can directly spread upon the affected part.
Embodiment 3
Staphylococcus lysozyme 0.001 gram, lysozyme 0.01 gram, chitin 5 grams, starch 5 grams, polyethylene glycol 1500 20 grams.
Said components is proportionally added respectively in the sterile chamber,, can add an amount of water, stir, can be made into gel, directly spread upon the affected part as needs.

Claims (12)

1. a biologic product that is used for the foot sterilization is characterized in that, comprises that weight percent content is the staphylococcus lysozyme of 0.0001-0.1% and pharmaceutically acceptable carrier.
2. the biologic product that is used for foot sterilization according to claim 1 is characterized in that, said carrier comprises that water, gel are with matrix or cream matrix;
Gel comprises in glycerin gelatine, starch, cellulose derivatives, the polyethylene glycol one or more with matrix;
Cream comprises one or more and emulsifier in hydroxyl class, grease class or the lipoid with matrix.
3. the biologic product that is used for foot sterilization according to claim 2 is characterized in that, the hydroxyl class comprises a kind of in vaseline, solid paraffin, atoleine or the silicone; The grease class comprises a kind of in peanut oil, cotton seed oil or the hydrogenated vegetable oil; Lipoid comprises a kind of in lanolin, beeswax or the cholesterol; Cream comprises one or more in naturally occurring emulsifying agent or the synthetic emulsifier.
4. the biologic product that is used for the foot sterilization according to claim 1, it is characterized in that staphylococcus lysozyme is one or more in agriotype, reorganization generation, mutant or any reorganization that contains the glycine cross-bond that keeps the antistaphylohemolysin whole cell peptidoglycan or the relevant enzyme.
5. according to each described biologic product that is used for the foot sterilization of claim 1～4, it is characterized in that, also contain the lysozyme that weight percent content is 0.001-5% in the said preparation.
6. according to each described biologic product that is used for the foot sterilization of claim 1～4, it is characterized in that, also contain the protein stabilizing agent that weight percent content is 0.5-50% in the said preparation, protein stabilizing agent comprises polyethylene glycol substances or shitosan, chitin or N-acetyl-D-amino.
7. according to each described biologic product that is used for the foot sterilization of claim 1～4, it is characterized in that, also comprise the emollient of preparation total amount 0.5～20% and an amount of emulsifier.
8. the biologic product that is used for the foot sterilization according to claim 6 is characterized in that, also comprises the emollient of preparation total amount 0.5～20% and an amount of emulsifier.
9. the biologic product that is used for the foot sterilization according to claim 5 is characterized in that, also comprises the emollient of preparation total amount 0.5～20% and an amount of emulsifier.
10. the biologic product that is used for the foot sterilization according to claim 1 is characterized in that said preparation is aqua, gel or cream.
11. the biologic product that is used for the foot sterilization according to claim 8 is characterized in that said preparation is aqua, gel or cream.
12. the biologic product that is used for the foot sterilization according to claim 9 is characterized in that said preparation is aqua, gel or cream.
CNB2003101079830A 2003-10-16 2003-10-16 Biological agent for foot disinfection Expired - Lifetime CN100431419C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2003101079830A CN100431419C (en) 2003-10-16 2003-10-16 Biological agent for foot disinfection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2003101079830A CN100431419C (en) 2003-10-16 2003-10-16 Biological agent for foot disinfection

Publications (2)

Publication Number Publication Date
CN1528150A true CN1528150A (en) 2004-09-15
CN100431419C CN100431419C (en) 2008-11-12

Family

ID=34304585

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003101079830A Expired - Lifetime CN100431419C (en) 2003-10-16 2003-10-16 Biological agent for foot disinfection

Country Status (1)

Country Link
CN (1) CN100431419C (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101757615A (en) * 2008-11-26 2010-06-30 上海高科联合生物技术研发有限公司 Ointment for clearing nose planted staphylococcus aureus and preparing method thereof
CN103877215A (en) * 2014-04-14 2014-06-25 宋巍 Chinese herbal medicine disinfection and sterilization foot-caring solution
CN104338123A (en) * 2013-07-25 2015-02-11 张荣富 Enzyme-containing footbath solution
CN104721812A (en) * 2014-12-16 2015-06-24 杨陈 Lysostaphin compound enzyme disinfectant and preparation method thereof
CN108743927A (en) * 2018-08-28 2018-11-06 湖北煜韩环境科技有限公司 A kind of pulvis and preparation method thereof except foot odour

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100450546C (en) * 2002-01-28 2009-01-14 上海高科生物工程有限公司 Compound preparation for dissolving staphyloase and preparation method

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101757615A (en) * 2008-11-26 2010-06-30 上海高科联合生物技术研发有限公司 Ointment for clearing nose planted staphylococcus aureus and preparing method thereof
CN104338123A (en) * 2013-07-25 2015-02-11 张荣富 Enzyme-containing footbath solution
CN103877215A (en) * 2014-04-14 2014-06-25 宋巍 Chinese herbal medicine disinfection and sterilization foot-caring solution
CN104721812A (en) * 2014-12-16 2015-06-24 杨陈 Lysostaphin compound enzyme disinfectant and preparation method thereof
CN108743927A (en) * 2018-08-28 2018-11-06 湖北煜韩环境科技有限公司 A kind of pulvis and preparation method thereof except foot odour

Also Published As

Publication number Publication date
CN100431419C (en) 2008-11-12

Similar Documents

Publication Publication Date Title
CN1307971C (en) Antimycotic nail varnish composition
CN102655754B (en) Antimycotic mixture comprising fungal organism pythium oligandrum
CN1203864C (en) Spray formulation of providone iodine
JP5117193B2 (en) Arthrospira-based compositions and uses thereof
KR101532070B1 (en) Composition for infected scalp and damaged hair using sulfur and fermented protein and method for manufacturing the same
CN1883273A (en) Active disinfectant germicide and method for preparing same
CN1367018A (en) Compound preparation of staphylococcolysis enzyme and its preparation method and application
JP2005200339A (en) Antimicrobial agent
CN1528150A (en) Biological agent for foot disinfection
CN1309304C (en) Sterilizing gel, preparing method and application thereof
CN1209972C (en) Sterilization formulation and wet tissue, preparation method and use
CN100335126C (en) Preparation for preventing and curing endometritis for dairy cattle and preparing method thereof
CN101288769A (en) Bactericide for pet and preparation method thereof
CN1528138A (en) Foot disinfectant
CN1415209A (en) Method for preparing the bactericide and the cleansing facial milk]
CN1128614C (en) Use of dichlorobenzyl alchol for preparing a preparation for topical treatment of inflammation and preparation containing dichlorobenzyl alchol
CN1238054C (en) Biotechnological formulation for suppressing and killing helicobacter pylori, its preparation and use
CN1144579C (en) Composition for enhancing oral hygiene
BR112015032961B1 (en) FORMULATION, AND, METHODS TO TREAT HUMAN OR ANIMAL WASTE AND TO ELIMINATE OR REDUCE MICROBIAL GROWTH IN A TREATMENT PLACE
CN1823702A (en) Oral cavity health protection composition and its preparation method
CN1157230C (en) Bactericidal gauze with lysostaphin complex enzyme
CN1853480A (en) Broad-spectrum antiseptics and production thereof
CN1743027A (en) Silver-contained oral-cavity cleaning article
WO2020069407A1 (en) Volatile organic compound formulations having antimicrobial activity
CN1511586A (en) Oral digestible film and its preparing process and use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20081112

CX01 Expiry of patent term